The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

By sjmartinez • April 27, 2025

Golub LS, Manubolu VS, Aldana-Bitar J, Dahal S, Verghese D, Alalawi L, Krishnan S, Kianoush S, Benzing T, Ichikawa K, Kinninger A, Fazlalizadeh H, Pourafkari L, Ahmad K, Susarla S, Mangaoang C, Ghanem AK, Javier DA, Hamal S, Roy SK, Budoff MJ. The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial. Nutr Metab Cardiovasc Dis. 2025 Apr 5:104036. doi: 10.1016/j.numecd.2025.104036. Epub ahead of print. PMID: 40287313.

Tags: ASCVD, atherosclerotic cardiovascular disease, CAC, Cardiology/Epi, cardiovascular disease, Computed Tomography Angiography, coronary artery calcium, CTA, CVD, General Internal Medicine, GLP1 receptor agonists, Harbor UCLA, HCC, Hepatocellular carcinoma, MASH, MASLD, Metabolic dysfunction-associated Steatohepatitis, Metabolic dysfunction-associated steatotic liver disease, Publications, randomized trial, Resident, semaglutide

P2Y12 Inhibitors and Mortality in Patients Hospitalized With Intracerebral Hemorrhage

Jin C, Song Y, Mac Grory B, Sun JL, Alhanti B, Fonarow GC, Schwamm LH, Sheth KN, Smith EE, Messé SR, Saver JL, Bhatt DL,[...]

Clinical Triage of Individuals With Warning Symptoms of Imminent Cardiac Arrest

Reinier K, Chugh H, Kadiyala V, Sargsyan A, Uy-Evanado A, Nakamura K, Heckard E, Mathias M, Grogan T, Elashoff D, Salvucci A, Jui J, Chugh[...]

Nuclear mechanotransduction: tools for mechanical perturbation and chromatin characterization

Soto J, Origer N, Wu Y, Cardenas Benitez B, Massad R, Rahgoshay D, Lee A, Downing T, Li S. Nuclear mechanotransduction: tools for mechanical perturbation[...]